

FDG PET Bibliography

Coleman RE, Czernin J. Commentary. *Mol. Imaging Biol.* 2007; 9:323

Manning K, Tepfer B, Goldklang G, et al. Clinical Practice Guidelines for the Utilization of Positron Emission Tomography/Computed Tomography Imaging in Selected Oncologic Applications: Suggestion from a Provider Group. *Mol. Imaging Biol.* 2007; 9:324-332.

Erturk SM, Van den Abbeele AD. Role of PET/CT Scanning in Initial and Post-Treatment Assessment of Hodgkin Disease. *JNCCN.* 2008; 6:623-632.

Gold MA. PET in Cervical Cancer- Implications for `Staging,` Treatment Planning, Assessment of Prognosis, and Prediction of Response. *JNCCN.* 2008; 6:37-45.

Gillies RJ, Robey I, Giatenby RA. Causes and Consequences of Increased Glucose Metabolism of Cancers. *J. of Nucl. Med.* 2008; 49:24S-42S.

Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development. *Clin. Cancer Res.* 2005; 11:2785-2808.

Mankoff DA, Eary JF, Link JM, et al. Tumor-Specific Positron Emission Tomography Imaging in Patients: [¹⁸F] Fluorodeoxyglucose and Beyond. *Clin. Cancer Res.* 2007; 13:3460-3469.

Podoloff DA, Advani RH, Allred C, et al. NCCN Task Force Report: PET/CT Scanning in Cancer. *JNCCN.* 2007; 5: Supplement 1.

Juwied ME, Stroobants S, Hoekstra OS, et al. Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. *J. Clin. Oncol.* 2007; 25:571-578.

Gambhir SS, Czernin J, Schwimmer J, et al. A Tabulated Summary of the FDG PET Literature. *J. of Nucl Med.* 2001; 42:1S-93S.

Colorectal Cancer

Wiering B, Oyen W, Van der Sijp J, et al. Improved Selection of Patients for Hepatic Surgery of Colorectal Liver Metastases with FDG-PET: A Randomized Study, *Proceedings of ASCO*, 2008.

Breast Cancer:

Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and Breast Cancer Imaging. *Radiographics.* 2007; 27:S215-S229.

Danforth DN, Aloj L, Carrasquillo JA, et al. The role of ¹⁸F-FDG-PET in the local/regional evaluation of women with breast cancer. *Breast Cancer Research and Treatment.* 2002; 75:135.

van der Hoeven JJ, Krak NC, Hoekstra OS, et al. ¹⁸F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. *J. Clin Oncol.* 2004; 22:1253-1259.

Small Cell Lung Cancer:

Bradley JD, Dehdashti F, Mintun MA, et al. Positron Emission Tomography in Limited-Stage Small-Cell Lung Cancer: A Prospective Study. *J. Clin. Oncol.* 2004; 22:3248-3254.

Gulenchyn K, Maziak D, Darling G, et al. Ontario Oncology Trials to Evaluate the Clinical and Economic Impact of ¹⁸F-FDG PET. *J. Nucl. Med.* 2008; 49.

Brink TS, Mix M, Ruhland S, et al. Impact of [¹⁸F]FDG-PET on the primary staging of small-cell lung cancer. *EJNM.* 2004; 31:1614-1620.

Fischer BM, Mortensen J, Langer SW, et al. A Prospective Study of PET/CT in Initial Staging of Small-Cell Lung Cancer: Comparison with CT, Bone Scintigraphy and Bone Marrow Analysis. *Annals of Oncology.* 2007; 8:338-345.

Cervical Cancer Re-Staging:

Schwarz JK, Siegel BA, Dehdashti F, et al. Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma. *JAMA.* 2007; 298:2289-2295.

Ovarian Cancer:

Risum S, Hogdall C, Loft A, et al. The Diagnostic Value of PET/CT for Primary Ovarian Cancer- A Prospective Study. *Gynecologic Oncology.* 2007; 105:145-149.